Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

Mon, 29th Oct 2018 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC, up 4.7%. The Asia-focused bank reported an "encouraging" third quarter with consensus beating profit. For the three months ended September, pretax profit rose 28% to USD5.92 billion from USD4.62 billion the year prior. Excluding the impact of currency translation, pretax profit rose 16% on the year before. Revenue rose 1.6% to USD13.80 billion from USD13.58 billion the year before. Revenue performance was driven by "strong" growth in all of HSBC's three main global businesses. Shore Capital called HSBC's third-quarter results strong, saying adjusted pretax profit of USD6.19 billion, up 16% on year, was 8% better than consensus at USD5.73 billion and 6% better than Shore's own forecast of USD5.86 billion. Group operating expenses decreased 6.8% to USD7.97 billion from USD8.55 billion the year before. This is largely due the bank's significant items decreasing to USD228 million from USD762 million. The large drop in one-off costs included the non-recurrence of "costs to achieve", which had been USD700 million in the year-ago comparative period. ----------Shire, up 2.5%. Japanese drugmaker Takeda Pharmaceutical said it is considering selling an experimental inflammatory bowel disease drug that is under development by its takeover target Shire. Takeda confirmed its discussion with the European Commission regarding potential overlap between its marketed product Entyvio and Shire's pipeline compound SHP647. SHP647 is a human monoclonal antibody that targets mucosal addressin cell adhesion molecule, which is currently undertaking phase III clinical trials. Takeda has proposed a potential divestment of SHP647 and associated rights. Takeda confirmed on Monday that there are no discussions with the European Commission regarding any other marketed products or assets in the pipeline.----------FTSE 100 - LOSERS----------Just Eat, down 5.2%. Peel Hunt downgraded the online takeaway platform to Sell from Buy. The broker said the rise of rivals Uber and Deliveroo could lead to the demise of Just Eat, given the two can outspend the FTSE 100 constituent and outperform in the smartphone space. Bloomberg in September reported that ride-hailing app Uber - which also offers a food delivery service Uber Eats - was in early discussions with Deliveroo, as part of its strategy to invest and partner with rivals ahead of its planned initial public offering next year.----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 20%. The cancer-focused pharmaceutical company's shares rose after a key research study demonstrated positive results for its Nuvec delivery system. Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin. The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems. As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required. In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.----------Lok'n Store, up 10%. The storage company said its earnings grew in its recently ended financial year following a rise in occupancy and store numbers. Lok'n Store said pretax profit in the year to the end of July improved to GBP5.3 million from GBP4.0 million reported a year earlier, as revenue rose to GBP17.8 million from GBP16.7 million. The company noted the result was driven by occupancy increases in both old and new stores. Tight control over operating costs led to a 2% increase in self-storage margins, which has also contributed in pushing the company's profit to "record level". Lok'nStore declared an annual dividend of 11 pence per share, up 10% from 10p paid the year prior.----------OTHER MAIN MARKET AND AIM - LOSERS----------Warpaint Group, down 43%. The colour cosmetics supplier said the UK market has remained challenging for the company with softening sales, even as it expects a rise in profit and revenue for 2018. Warpaint said its UK market, which accounted for 44% of group's sales in the first half of the year, saw further softening following the end of the interim period due to retailers reducing their stock levels and Christmas orders. The group said the reduction in previously anticipated UK sales will hurt its performance for 2018, which will not be completely offset by an outperformance in its sales territories overseas. As at September 30, sales in the US were up 60% compared to the same period in 2017, and sales in the EU were up 14% year-on-year.----------Gama Aviation, down 17%. The aviation service provider lowered its full-year expectations after trading in some of its divisions has not improved "sufficiently" during the second half of 2018. Gama said it now expects the annual underlying operating profit to be USD3 million below its original expectations. In 2017, Gama generated underlying operating profit of USD18.7 million. On a divisional basis, the company's Air unit saw stable performance in Europe, Middle East & Asia. However, profit from the US is now below Gama's expectations due to slower-than-anticipated growth in charter and aircraft management revenue. In Asia, Gama's associate China Air Services has continued to underperform with the unexpected loss of contracts significantly harming margins. ----------
More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.